Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth (Status and Outlook) 2023-2029

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Forecast” looks at past sales and reviews total world B-Cell Maturation Antigen (BCMA) Targeted Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected B-Cell Maturation Antigen (BCMA) Targeted Therapies sales for 2023 through 2029. With B-Cell Maturation Antigen (BCMA) Targeted Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world B-Cell Maturation Antigen (BCMA) Targeted Therapies industry.

This Insight Report provides a comprehensive analysis of the global B-Cell Maturation Antigen (BCMA) Targeted Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on B-Cell Maturation Antigen (BCMA) Targeted Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for B-Cell Maturation Antigen (BCMA) Targeted Therapies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global B-Cell Maturation Antigen (BCMA) Targeted Therapies.

The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for B-Cell Maturation Antigen (BCMA) Targeted Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for B-Cell Maturation Antigen (BCMA) Targeted Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for B-Cell Maturation Antigen (BCMA) Targeted Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key B-Cell Maturation Antigen (BCMA) Targeted Therapies players cover Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute and Deerfield Partners, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of B-Cell Maturation Antigen (BCMA) Targeted Therapies market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells

Segmentation by application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.